Background. Adrenocortical carcinoma is a rare neoplasm with a poor prognosis. Conversely, adrenocortical adenomas are common and benign. Despite their shared histologic origin, little evidence exists to suggest that adrenocortical adenoma arises from adrenocortical carcinoma. Recent genetic analyses of adrenocortical carcinoma have shown recurrent gene copy deletion of CYP4B1, a cytochrome P450 isozyme. This study investigates a potential role for CYP4B1 in modulating adrenocortical tumorigenesis and/or conferring chemoresistance to adrenocortical carcinomas. Methods. Using TaqMan, real-time quantitative polymerase chain reaction techniques, we investigated CYP4B1 expression in normal adrenal cortex (n = 10), histologically confirmed adrenocortical adenomas (n = 10), and adrenocortical carcinomas (n = 10). Adrenocortical carcinoma cell lines were enforced to express CYP4B1, and effects on cell death and enhanced mitotane and cisplatin sensitivity were tested.
ADRENOCORTICAL CARCINOMA (ACC), a rare endocrine malignancy that portends a poor prognosis, occurs in 0.5-2 people per million per year, and confers a 5-year survival of only 16-38%. [1] [2] [3] [4] The majority of these carcinomas (65-85%) will exhibit hormonal hypersecretion of cortisol, aldosterone, or sex steroids but can be nonfunctional as well. 5 Due in part to its rarity, the underlying molecular and genetic pathogenicity of ACC is poorly understood.
The lack of reliable genetic markers undermines therapeutic decision-making and causes substantial problems in diagnosis, prognosis, and management.
Inherited disorders, such as BeckwithWiedemann syndrome and Li-Fraumeni, are found in a subset of patients; however, the majority of cases are sporadic. 2, 6 Investigators have focused on rare genetic mutations in known oncogenes, such as TP53, IGF2, and APC, but the benefits of this research have yet to reach patients. 1, 7 While increased access to high-throughput sequencing has facilitated exploration of the genetic landscape of ACC, complete R0 surgical resection remains the only prospect for a durable cure. 5, 8 Advances in treatment have been limited due to the inherent chemoresistance and lack of knowledge of the molecular drivers of ACC. Mitotane (1,1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl] ethane), the classic, first-line agent in the treatment of ACC, acts by lysing adrenal cortical cells directly and can decrease hormone hypersecretion. Recent data suggest that combination therapy with cisplatin may increase response rates and progression-free survival. 9, 10 Altered cellular metabolism is a prominent feature of ACC and is an important area for oncologic research. 7 Essential elements in this system are the cytochrome P450 (CYP) enzymes. This superfamily consists of >50 heme-thiolate proteins that play essential roles in both the biosynthetic and catabolic pathways of vitamins, fatty acids, prostaglandins, bile acids, and steroids. Steroid production can influence strongly cancer growth and affect cellular metabolism, especially in endocrine organs like the adrenal gland.
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CYP enzymes constitute one of the most important mechanisms for human drug metabolism and thus are of central importance in chemoresistance. Altered CYP expression increases rates of anticancer drug degradation, decreasing the intended cytotoxic effect. 12, 13 Additionally, while not considered typical oncogenes or tumor suppressors, differential expression of cytochrome P450 genes has been associated with pancreatic, breast, bladder, and lung cancer. [14] [15] [16] [17] Recent bioinformatic analysis of copy number variations in ACC displayed widespread genomic instability and multiple arm-level and focal alterations in the cytochrome P450 genes. 18 Among the CYP genes, cytochrome P450 4B1 (CYP4B1) was found to be deleted in numerous samples. Because of the crucial functions of CYP enzymes in steroid metabolism and the physiology of the adrenal gland, we investigated the potential role of CYP4B1 in both benign and malignant adrenocortical neoplasms.
CYP4B1 is unique among the cytochrome P450 class in that it is involved in both endobiotic and xenobiotic metabolism. It hydroxylates selectively fatty acids and may exert toxicologic effects via activation of aromatic amines whose byproducts can be cytotoxic under specific conditions. 19 Research on bladder cancer has demonstrated that the absence of wild-type CYP4B1 is associated with tumor carcinogenesis. 17 Additionally, CYP4B1 has differential expression patterns in lung cancer compared to normal tissue. 15 The association of CYP4B1 with other malignancies and the demonstrated copy number loss in ACC led us to investigate its potential role in adrenocortical neoplasms. were selected for the study to ensure that current clinical and genetic testing protocols would be followed during diagnostic evaluation. All adrenal tissue samples were examined by an experienced endocrine pathologist for histologic identification. Additional formalin-fixed, paraffin-embedded samples from the same patients were used for immunohistochemistry.
METHODS
Written informed consent was obtained from all patients involved in this study and protected health information was acquired and maintained in accordance with regulations as specified by the Health Insurance Portability and Accountability Act. The consent waiver and all procedural aspects of this study were approved by the Yale University Institutional Review Board.
Gene expression analysis. RNA was isolated from fresh frozen samples using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). Quantity and quality of isolated RNA was assessed by spectrophotometry (NanoDrop Technologies, Wilmington, DE). Two-hundred ng of RNA was used for cDNA synthesis with the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). Quantitative, reverse transcriptase-polymerase chain reaction was performed on a CFX96 Real-Time System thermocycler (Bio-Rad) using TaqMan PCR master mix with primers and probes specific to CYP4B1 (all from Applied Biosystems, Foster City, CA). Relative expression between samples was normalized to endogenous ribosomal protein, large, P0 (RPLP0) expression levels. Two independent experiments were performed with duplicate samples for all assays. Relative expression levels were calculated using the Livak method. 20 Immunohistochemical analysis. Five-mm thick sections of histologically confirmed ACC, ACA, and normal adrenal tissue from formalin-fixed, paraffin-embedded tissue samples were collected for study. Two representative samples of each tissue type were selected for immunostaining. Using standard immunohistochemistry protocols, target epitopes were detected using rabbit anti-CYP4B1 polyclonal antibody (Santa Cruz, Dallas, TX) followed by antirabbit horseradish peroxidase conjugated monoclonal secondary antibody (Santa Cruz). 21 DAB (3,39-diaminobenzidine tetrahydrochloride) was utilized for antigen detection (Life Technologies, Carlsbad, CA). Sections were counterstained with hematoxylin and mounted using immunohistomount (Santa Cruz).
Ectopic expression of CYP4B1 in ACC cell lines. Standard cell culture experiments were performed as described previously. 21 The human ACC cell lines SW-13 and NCI-H295R were purchased from the American Type Culture Collection (Manassas, VA). SW-13 cells were maintained under sterile conditions in Dulbecco's Modified Eagle's medium supplemented with 10% certified fetal bovine serum and 10,000 U/mL penicillin/streptomycin (Life Technologies) in a standard humidified incubator at 37.08C and 5% CO 2 . NCI-H295R cells were grown in Dulbecco's Modified Eagle's medium/F-12 containing 5% NuSerum, 0.1% ITS premix, and 10,000 U/mL penicillin/streptomycin (Life Technologies). Myc-DDK-tagged pCMV6-Entry, pCMV6-Entry/green fluorescent protein (GFP), and pCMV6-Entry/ CYP4B1 plasmid vectors (Origene, Rockville, MD) were used to transfect cells that were grown to 70-80% confluence.
Transient transfection was performed in 24-well plates using Lipofectamine 2000 according to the manufacturer's recommendations (Life Technologies). Transfection efficiencies were determined by quantifying the percentage of GFP-expressing cells from parallel transfections carried out using pCMV6-Entry/GFP vectors; 24 h after transfection, cells were treated with chemotherapy agents or the appropriate diluents. Mitotane and cisplatin were dissolved in 100% ethanol or distilled water respectively (Spectrum Chemical, New Brunswick, NJ). Cells were treated with either (1) mock, (2) mitotane 5 mM, (3) mitotane 50 mM, (4) mitotane 50 mM plus cisplatin 700 nM, or (5) untreated. After 24 h of treatment, cell viability was measured using a Trypan blue assay. 21 A minimum of 2 independent experiments were performed with duplicate samples in each assay. The standard Student t test was used to assess statistical significance in normally distributed data sets. A P value < .01 was considered significant.
RESULTS
Patient characteristics. Both the ACA and ACC groups had a predominance of female patients with 60% and 80%, respectively. Age (mean ± standard deviation) at the time of operation was 56 ± 10 for ACC and 46 ± 14 in ACA. Mean tumor diameter was nearly 9 cm greater in ACC than ACA (ACC = 11.3 cm [6.0-14.0]; ACA = 2.5 cm [1.1-6.1]). The majority of neoplasms had biochemically unequivocal hormone hypersecretion. ACCs were more often cortisol producing (4/10), while 50% of ACAs secreted aldosterone (5/10; Table) .
Decreased expression of CYP4B1. Gene expression analyses demonstrated suppression of CYP4B1 in 100% of ACA (10/10) and ACC (10/10) samples when compared with adjacent histologically normal adrenal tissue (Fig 1) . Overall, there was a correlation between tumor dedifferentiation and decreased CYP4B1 expression. Average relative expression of CYP4B1 in ACA was 0.19 (0.01-0.50) and was decreased compared to expression levels in the normal adrenal cortex (P < .01; Fig  1) . Expression was nearly absent in ACC samples and less than ACA and normal (average = 0.01; 0.00-0.05; P < .01; Fig 1) .
Immunohistochemical detection of protein expression. Histologically confirmed ACA, ACC, and normal adrenal samples were chosen from among the cohort to evaluate expression of CYP4B1 protein. In normal adrenal tissue, immunostaining in the cytoplasmic and perinuclear regions was observed. Overall protein levels in ACA were decreased markedly compared to normal and undetectable in ACC (Fig 2) .
Enforced expression of CYP4B1 in ACC cells. Stable transfection of CYP4B1 in NCI-H295R cells resulted in immediate loss of viability. Stable, neomycin-resistant SW-13 cells were selected and also eventually lost the ability to express CYP4B1. Because the enforced stable expression of CYP4B1 appeared to be toxic to both ACC cell lines, we performed transient expression of CYP4B1 in the relatively more tolerant SW-13 cells Surgery Volume 161, Number 1 to determine if the presence of the protein was initiating cytotoxicity. Cells were also tested to determine whether standard ACC chemotherapy agents accentuate CYP4B1-promoted cytotoxicity.
The effects of the medications tested were similar to those reported previously. 22 As could be predicted from the outcome of stable expression, expression of CYP4B1 alone was sufficient to promote loss of ACC cell viability (Fig 3, A) . This pattern of CYP4B1-promoted cellular toxicity persisted independent of the chemotherapy regimen tested (Fig 3, A) . While treatment of control cells with low-dose mitotane therapy (5 mM) did not result in cytotoxicity, cells transfected to express CYP4B1 had decreased viability and increased cell death (P < .01; Fig 3,  B) . Addition of cisplatin to mitotane resulted in increased loss of viability compared to mitotane (50 mM) alone and was further accentuated by the expression of CYP4B1. These experiments suggest a role for CYP4B1 in sensitizing dedifferentiated adrenocortical cells to cell death.
DISCUSSION
While the molecular etiopathogenesis of adrenocortical carcinogenesis has yet to be fully characterized, substantive advances have been made in understanding the disease, but cataloging the genetic and epigenetic changes that initiate and drive ACC has been stifled by both its rarity and inherent genetic complexity. Specifically lacking are studies that explore the effects of genetic change in the context of the complex metabolic milieu of the adrenal cortex. This study focuses on the potential role of a seminal member of the CYP family in the initiation or progression of ACCs.
In this study, we demonstrate a marked decrease in expression of CYP4B1 in 100% of both benign and malignant adrenocortical neoplasms, a previously undescribed event of potential metabolic and carcinogenic significance. Although the mechanism underlying the observed sequential suppression of CYP4B1 in these neoplasms has not been clarified completely, loss of copy number appears to contribute to the silencing of CYP4B1. Alternatively, epigenetic alteration may be a more dominant influence, as the global silencing observed in all adrenocortical neoplasms studied would not be explained by the lesser degree of gene copy loss. 23 Moreover, the downregulation appears to follow a graded trend along with the dedifferentiation of the adrenal cortex (Fig 2) .
CYP4B1 dysregulation has been noted in numerous malignancies. Unlike the present study, bladder neoplasms show an upregulation, not suppression, of CYP4B1, 17, 24 but this shift appears to be associated only with allelic variants and is not observed in the wild-type protein. 17 Repressed activity of CYP4B1 through missense mutations and deletions may allow malignant transformation. It is very likely that the metabolically intense, endocrine physiology of the adrenal gland requires CYP4B1 for steroid synthesis, which, when perturbed, may lead to metabolic chaos and cell death. Because a specific role for CYP4B1 in the normal adrenal cortex is not yet known, it is difficult to speculate on the impact of its dysregulation or the possible effects of its silencing on adrenocortical dedifferentiation or carcinogenesis.
Of special interest is the observation that both transient and stable expression of CYP4B1 resulted in toxicity in 2, well-studied ACC cell lines. Although the effect needs to be confirmed using inducible promoters, the preliminary results point toward a tumor suppressor role for CYP4B1 in ACC. The mechanism by which an enzyme expressed uncommonly in other tissues maintains a gatekeeper function in the context of the adrenal cortex is of immense interest and needs to be studied further. 25 The results of our experiments assessing the cytotoxic effect of CYP4B1 further support its role as a cell-death promoter in adrenocortical neoplasms. Treatment with both mitotane and cisplatin in CYP4B1-expressing cells decreased viability in the 2 ACC cell lines studied. In the doses and combinations tested, the expression of CYP4B1 appears to accentuate toxicity irrespective of the agent used. It is also noteworthy that CYP4B1 expression promoted cytotoxicity in SW-13 cells with low-dose mitotane (5 mM; Fig 3, A  and B) . This apparent chemosensitization may prove to be important clinically, because it may confer increased efficacy to anticancer drugs. Increasing local effective concentrations of peritumoral chemotherapy effectively shifts the doseresponse curve, potentially decreasing the risk of systemic toxicity. 
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Despite their common histologic origin and shared profile of hormone secretion, there is little evidence that ACC arises from ACA. The graded decrease in expression of CYP4B1 and the observed correlation with adrenal dedifferentiation suggest at least a physiologic parallel between these distinct neoplasms. In conclusion, this study offers new insight into the potential roles of CYP4B1 in the overall process of adrenal tumorigenesis and ACC chemoresistance.
DISCUSSION
Dr Brian R. Untch (New York, NY): I have a question about the correlation between this deletion that you are finding and the genotypes from the exome sequencing. Was there a specific set of mutations that correlated with this deletion?
Secondly, we know that the beta catenin pathway is important in ACC, and I am wondering if there is any relationship to beta catenin pathway activation and this deletion.
Dr Timothy D. Murtha: I think that it is interesting to look at the correlation between different gene expressions and deletions. When we looked at our exome sequencing---this was the resident previous to my work---she found that there was true genetic chaos within these cells and that finding correlation between them was relative. So I think that is something to look forward to in the future, but at this time it is something that we have not invested much time in yet. Dr Erin A. Felger (Washington, D.C.): I am just curious to know where your normal samples actually came from.
Dr Timothy D. Murtha: The samples were from adrenal tissues that were adjacent to the ACA samples, and we took from those histologically via trained endocrine pathologists, but, of course, it is always difficult to determine what is a true normal.
Dr Naris Nilubol (Bethesda, MD): I wonder if you could tell me if expression is associated with any functionality of the tumor at all, 4B1, in terms of adenoma, functioning, nonfunctioning.
Dr Timothy D. Murtha: We actually looked at that, and there was no statistical difference between the amount of expression and the support we wanted. It is difficult to say in ACC as there was a global decrease, but there was none seen in ACAs at least.
Dr Jennifer Rosen (Washington, D.C.): Is the reason why you included ACAs as well as ACCs, do you have an underlying hypothesis there? Do you see this as being a continuum from normal to ACA to ACC, which is a rather contentious discussion?
Dr Timothy D. Murtha: Absolutely. It is definitely something that we considered, and I think that we can say there is at least a physiologic parallel between the ACAs and ACCs. However, I do not think that this work can conclusively say that one is derived from the other, but I think it is an interesting point worth looking into.
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